An off-the-shelf approach in identifying novel GVL mHAs

Article

A recent study has found that novel graft-versus-leukemia has minor histocompatibility antigens and was all validated.

A recent study has found that novel graft-versus-leukemia has minor histocompatibility antigens and was all validated.

A recent study has found that novel graft-versus-leukemia has minor histocompatibility antigens and was all validated.

Researchers from the University of North Carolina at Chapel Hill have recently published an article describing their discovery of novel graft-versus-leukemia (GVL) shared minor histocompatibility antigens (mHAs), 24 of which the authors further validated. The group utilized the DISCOVeRY-BMT data set. These findings, published in Blood Advances, highlight an innovative approach that can be used to validate additional undiscovered GVL mHAs and improve current immunotherapeutic abilities by increasing the number of known GVL mHAs.

This study aimed to enhance the mHA discovery process from the current “personalized” approach, which identifies mHAs suitable for a small number of patients, to an “off-the-shelf” approach, which allows for a substantially increased amount of mHAs discoveries.

Three common HLA alleles, HLA-A*02:01, HLA-B*35:01, and HLA-C*07:02, were chosen for further investigation to grant the study 100% GVL mHA peptide coverage, based on 11 to 15 peptides. Mass spectrometry validated the HLA presentation of the GVL mHAs in question using samples from cell line samples U937A2, NB4, and MONOMAC1 respectively. For HLA-A*02:01, 17 peptides were positively identified, 16 being novel; for HLA-B*35:01, three novel peptides were identified; and for HLA-C*07:02, five novel peptides were identified. Further, one novel predicted mHA was confirmed through flow cytometry tetramer staining of CD8 T-cells cultured with novel mHA-pulsed (UNC-HEX-DC-V) dendritic cells. Taken together, the authors of this study have demonstrated methods to identify novel shared GVL mHAs. This work provides an optimistic outlook in the future discovery of mHAs for immunotherapeutics.

Reference

Olsen KS, Jadi O, Dexheimer S, et al. Shared graft-versus-leukemia minor histocompatibility antigens in DISCOVeRY-BMT. Blood Adv. 2023;7(9):1635-1649. doi:10.1182/bloodadvances.202200886

Related Videos
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.
Considering notable adverse effects associated with treatment may be critical when selecting therapy options for those with CML.
Adverse effects associated with oral azacitidine in low- or intermediate-risk MDS are typically transient, according to Mikkael A. Sekeres, MD, MS.
Related Content